Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
